Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy

BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. METHODS: T...

Full description

Saved in:
Bibliographic Details
Published inCancer Vol. 116; no. 23; pp. 5517 - 5526
Main Authors Schultz, Luciana, Albadine, Roula, Hicks, Jessica, Jadallah, Sana, DeMarzo, Angelo M., Chen, Ying‐Bei, Neilsen, Matthew E., Gonzalgo, Mark L., Sidransky, David, Schoenberg, Mark, Netto, George J.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.12.2010
Wiley-Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
Abstract BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. METHODS: Tissue microarrays were constructed from 132 cystectomies (1994‐2002). Immunohistochemistry was performed for Pten, c‐myc, p27, phosphorylated (phos)Akt, phosS6, and 4E‐BP1. Markers were evaluated for pattern, percentage, and intensity of staining. RESULTS: Mean length of follow‐up was 62.6 months (range, 1‐182 months). Disease progression, overall survival (OS), and disease‐specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E‐BP1. Pten, p27, phosAkt, phosS6, and 4E‐BP1 expression correlated with pathologic stage (pathological stage; P<.03). Pten, 4E‐BP1, and phosAkt expression correlated with divergent aggressive histology and invasion. phosS6 expression inversely predicted OS (P = .01), DSS (P = .001), and progression (P = .05). c‐myc expression inversely predicted progression (P = .01). In a multivariate analysis model that included TNM stage grouping, divergent aggressive histology, concomitant carcinoma in situ, phosS6, and c‐myc expression, phosS6 was an independent predictor of DSS (P = .03; hazard ratio [HR], −0.19), whereas c‐myc was an independent predictor of progression (P = .02; HR, −0.38). In a second model substituting organ‐confined disease and lymph node status for TNM stage grouping, phosS6 and c‐myc remained independent predictors of DSS (P = .03; HR, −0.21) and progression (P = .03; HR, −0.34), respectively. CONCLUSIONS: We found an overall down‐regulation of mTOR pathway in bladder urothelial carcinoma. phosS6 independently predicted DSS, and c‐myc independently predicted progression. Cancer 2010. © 2010 American Cancer Society. Mammalian target of rapamycin pathway was overall down‐regulated in urothelial carcinoma. Phosphorylated S6 protein was an independent predictor of disease‐specific survival, and c‐myc was an independent predictor of progression.
AbstractList BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. METHODS: Tissue microarrays were constructed from 132 cystectomies (1994-2002). Immunohistochemistry was performed for Pten, c-myc, p27, phosphorylated (phos)Akt, phosS6, and 4E-BP1. Markers were evaluated for pattern, percentage, and intensity of staining. RESULTS: Mean length of follow-up was 62.6 months (range, 1-182 months). Disease progression, overall survival (OS), and disease-specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E-BP1. Pten, p27, phosAkt, phosS6, and 4E-BP1 expression correlated with pathologic stage (pathological stage; PP = .01), DSS (P = .001), and progression (P = .05). c-myc expression inversely predicted progression (P = .01). In a multivariate analysis model that included TNM stage grouping, divergent aggressive histology, concomitant carcinoma in situ, phosS6, and c-myc expression, phosS6 was an independent predictor of DSS (P = .03; hazard ratio [HR], -0.19), whereas c-myc was an independent predictor of progression (P = .02; HR, -0.38). In a second model substituting organ-confined disease and lymph node status for TNM stage grouping, phosS6 and c-myc remained independent predictors of DSS (P = .03; HR, -0.21) and progression (P = .03; HR, -0.34), respectively. CONCLUSIONS: We found an overall down-regulation of mTOR pathway in bladder urothelial carcinoma. phosS6 independently predicted DSS, and c-myc independently predicted progression. Cancer 2010. ? 2010 American Cancer Society.
Abstract BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. METHODS: Tissue microarrays were constructed from 132 cystectomies (1994‐2002). Immunohistochemistry was performed for Pten, c‐ myc , p27, phosphorylated (phos)Akt, phosS6, and 4E‐BP1. Markers were evaluated for pattern, percentage, and intensity of staining. RESULTS: Mean length of follow‐up was 62.6 months (range, 1‐182 months). Disease progression, overall survival (OS), and disease‐specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E‐BP1. Pten, p27, phosAkt, phosS6, and 4E‐BP1 expression correlated with pathologic stage (pathological stage; P <.03). Pten, 4E‐BP1, and phosAkt expression correlated with divergent aggressive histology and invasion. phosS6 expression inversely predicted OS ( P = .01), DSS ( P = .001), and progression ( P = .05). c‐ myc expression inversely predicted progression ( P = .01). In a multivariate analysis model that included TNM stage grouping, divergent aggressive histology, concomitant carcinoma in situ, phosS6, and c‐ myc expression, phosS6 was an independent predictor of DSS ( P = .03; hazard ratio [HR], −0.19), whereas c‐ myc was an independent predictor of progression ( P = .02; HR, −0.38). In a second model substituting organ‐confined disease and lymph node status for TNM stage grouping, phosS6 and c‐ myc remained independent predictors of DSS ( P = .03; HR, −0.21) and progression ( P = .03; HR, −0.34), respectively. CONCLUSIONS: We found an overall down‐regulation of mTOR pathway in bladder urothelial carcinoma. phosS6 independently predicted DSS, and c‐ myc independently predicted progression. Cancer 2010. © 2010 American Cancer Society. Mammalian target of rapamycin pathway was overall down‐regulated in urothelial carcinoma. Phosphorylated S6 protein was an independent predictor of disease‐specific survival, and c‐ myc was an independent predictor of progression.
BACKGROUNDBladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. METHODSTissue microarrays were constructed from 132 cystectomies (1994-2002). Immunohistochemistry was performed for Pten, c-myc, p27, phosphorylated (phos)Akt, phosS6, and 4E-BP1. Markers were evaluated for pattern, percentage, and intensity of staining. RESULTSMean length of follow-up was 62.6 months (range, 1-182 months). Disease progression, overall survival (OS), and disease-specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E-BP1. Pten, p27, phosAkt, phosS6, and 4E-BP1 expression correlated with pathologic stage (pathological stage; P<.03). Pten, 4E-BP1, and phosAkt expression correlated with divergent aggressive histology and invasion. phosS6 expression inversely predicted OS (P=.01), DSS (P=.001), and progression (P=.05). c-myc expression inversely predicted progression (P=.01). In a multivariate analysis model that included TNM stage grouping, divergent aggressive histology, concomitant carcinoma in situ, phosS6, and c-myc expression, phosS6 was an independent predictor of DSS (P=.03; hazard ratio [HR], -0.19), whereas c-myc was an independent predictor of progression (P=.02; HR, -0.38). In a second model substituting organ-confined disease and lymph node status for TNM stage grouping, phosS6 and c-myc remained independent predictors of DSS (P=.03; HR, -0.21) and progression (P=.03; HR, -0.34), respectively. CONCLUSIONSWe found an overall down-regulation of mTOR pathway in bladder urothelial carcinoma. phosS6 independently predicted DSS, and c-myc independently predicted progression.
BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. METHODS: Tissue microarrays were constructed from 132 cystectomies (1994‐2002). Immunohistochemistry was performed for Pten, c‐myc, p27, phosphorylated (phos)Akt, phosS6, and 4E‐BP1. Markers were evaluated for pattern, percentage, and intensity of staining. RESULTS: Mean length of follow‐up was 62.6 months (range, 1‐182 months). Disease progression, overall survival (OS), and disease‐specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E‐BP1. Pten, p27, phosAkt, phosS6, and 4E‐BP1 expression correlated with pathologic stage (pathological stage; P<.03). Pten, 4E‐BP1, and phosAkt expression correlated with divergent aggressive histology and invasion. phosS6 expression inversely predicted OS (P = .01), DSS (P = .001), and progression (P = .05). c‐myc expression inversely predicted progression (P = .01). In a multivariate analysis model that included TNM stage grouping, divergent aggressive histology, concomitant carcinoma in situ, phosS6, and c‐myc expression, phosS6 was an independent predictor of DSS (P = .03; hazard ratio [HR], −0.19), whereas c‐myc was an independent predictor of progression (P = .02; HR, −0.38). In a second model substituting organ‐confined disease and lymph node status for TNM stage grouping, phosS6 and c‐myc remained independent predictors of DSS (P = .03; HR, −0.21) and progression (P = .03; HR, −0.34), respectively. CONCLUSIONS: We found an overall down‐regulation of mTOR pathway in bladder urothelial carcinoma. phosS6 independently predicted DSS, and c‐myc independently predicted progression. Cancer 2010. © 2010 American Cancer Society. Mammalian target of rapamycin pathway was overall down‐regulated in urothelial carcinoma. Phosphorylated S6 protein was an independent predictor of disease‐specific survival, and c‐myc was an independent predictor of progression.
Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. Tissue microarrays were constructed from 132 cystectomies (1994-2002). Immunohistochemistry was performed for Pten, c-myc, p27, phosphorylated (phos)Akt, phosS6, and 4E-BP1. Markers were evaluated for pattern, percentage, and intensity of staining. Mean length of follow-up was 62.6 months (range, 1-182 months). Disease progression, overall survival (OS), and disease-specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E-BP1. Pten, p27, phosAkt, phosS6, and 4E-BP1 expression correlated with pathologic stage (pathological stage; P<.03). Pten, 4E-BP1, and phosAkt expression correlated with divergent aggressive histology and invasion. phosS6 expression inversely predicted OS (P=.01), DSS (P=.001), and progression (P=.05). c-myc expression inversely predicted progression (P=.01). In a multivariate analysis model that included TNM stage grouping, divergent aggressive histology, concomitant carcinoma in situ, phosS6, and c-myc expression, phosS6 was an independent predictor of DSS (P=.03; hazard ratio [HR], -0.19), whereas c-myc was an independent predictor of progression (P=.02; HR, -0.38). In a second model substituting organ-confined disease and lymph node status for TNM stage grouping, phosS6 and c-myc remained independent predictors of DSS (P=.03; HR, -0.21) and progression (P=.03; HR, -0.34), respectively. We found an overall down-regulation of mTOR pathway in bladder urothelial carcinoma. phosS6 independently predicted DSS, and c-myc independently predicted progression.
Author Hicks, Jessica
Neilsen, Matthew E.
Jadallah, Sana
Schoenberg, Mark
Netto, George J.
Albadine, Roula
Gonzalgo, Mark L.
Sidransky, David
Chen, Ying‐Bei
DeMarzo, Angelo M.
Schultz, Luciana
Author_xml – sequence: 1
  givenname: Luciana
  surname: Schultz
  fullname: Schultz, Luciana
– sequence: 2
  givenname: Roula
  surname: Albadine
  fullname: Albadine, Roula
– sequence: 3
  givenname: Jessica
  surname: Hicks
  fullname: Hicks, Jessica
– sequence: 4
  givenname: Sana
  surname: Jadallah
  fullname: Jadallah, Sana
– sequence: 5
  givenname: Angelo M.
  surname: DeMarzo
  fullname: DeMarzo, Angelo M.
– sequence: 6
  givenname: Ying‐Bei
  surname: Chen
  fullname: Chen, Ying‐Bei
– sequence: 7
  givenname: Matthew E.
  surname: Neilsen
  fullname: Neilsen, Matthew E.
– sequence: 8
  givenname: Mark L.
  surname: Gonzalgo
  fullname: Gonzalgo, Mark L.
– sequence: 9
  givenname: David
  surname: Sidransky
  fullname: Sidransky, David
– sequence: 10
  givenname: Mark
  surname: Schoenberg
  fullname: Schoenberg, Mark
– sequence: 11
  givenname: George J.
  surname: Netto
  fullname: Netto, George J.
  email: gnetto1@jhmi.edu
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23438165$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/20939013$$D View this record in MEDLINE/PubMed
BookMark eNp90cuKFDEUBuAgI07P6MYHkGxEEWrMpW5ZSjNeYFAQBXfFqdRJT6SStEmKsV7FpzVtt7qbTW5854TDf0HOfPBIyFPOrjhj4rX2Ol6JpmHiAdlwprqK8VqckQ1jrK-aWn47JxcpfS_XTjTyETkXTEnFuNyQX9c_9xFTssHTlCEviYKf6D6GnQ8pW02T3XlrrAavkQZDHTgHswVPM8Qd5sNbhD24VVtP95Bv72ClDt2IMdHytMSQb7FUzFRDLCg4OBQt0XqIKx1nmCaMFEwuq15TRp2DWx-ThwbmhE9O-yX5-vb6y_Z9dfPp3Yftm5tK10qKauwV9Fg3rZmg7VgzATTI23GSUE4TguHYMwQlTN-A7vnEsZaqnUbTKtS1vCQvjn3L0D8WTHlwNmmcZ_AYljT0XHDJhGqLfHmv5Ix3qmVdqwp9daQ6hpQimmEfrSvjFjQcUhsOqQ1_Uiv42anvMjqc_tG_MRXw_AQgaZhNLGHY9N_JWva8bYrjR3dnZ1zv-XLYftx-Pn7-G7cStgo
CODEN CANCAR
CitedBy_id crossref_primary_10_5858_arpa_2011_0471_RA
crossref_primary_10_1097_MOU_0b013e32834956d6
crossref_primary_10_1111_apm_12398
crossref_primary_10_1038_nrurol_2011_193
crossref_primary_10_1016_j_path_2012_08_003
crossref_primary_10_1186_s13046_017_0626_x
crossref_primary_10_1111_his_12209
crossref_primary_10_1016_j_humpath_2012_02_011
crossref_primary_10_1111_j_1464_410X_2011_10839_x
crossref_primary_10_1016_j_biopha_2020_111077
crossref_primary_10_1097_PAP_0b013e3182863f80
crossref_primary_10_1053_j_semdp_2013_11_005
crossref_primary_10_1530_ERC_11_0010
crossref_primary_10_1111_j_1464_410X_2012_11569_x
crossref_primary_10_1007_s00428_018_2302_8
crossref_primary_10_1038_s41698_019_0083_4
crossref_primary_10_1016_j_prp_2016_02_008
crossref_primary_10_1038_onc_2015_515
crossref_primary_10_1016_j_ctrv_2011_10_007
crossref_primary_10_1016_j_jaad_2013_04_027
crossref_primary_10_1097_MOU_0b013e328356ad0e
crossref_primary_10_1111_his_12338
crossref_primary_10_1016_j_urology_2012_09_007
crossref_primary_10_3389_fonc_2019_00466
crossref_primary_10_1016_j_humpath_2012_07_009
crossref_primary_10_1016_j_humpath_2015_07_024
crossref_primary_10_1093_carcin_bgs025
crossref_primary_10_1101_cshperspect_a036293
crossref_primary_10_1016_j_urology_2014_07_050
crossref_primary_10_4111_kju_2011_52_7_466
crossref_primary_10_3727_096504017X14957929842972
crossref_primary_10_5858_2010_0727_RAIR_1
crossref_primary_10_3892_ol_2014_2392
crossref_primary_10_1080_23808993_2016_1208049
crossref_primary_10_1002_jcb_27318
crossref_primary_10_1007_s13277_015_4678_2
crossref_primary_10_1016_j_acup_2014_12_002
crossref_primary_10_1016_j_urology_2012_04_032
crossref_primary_10_1016_j_juro_2017_06_096
crossref_primary_10_1111_j_1464_410X_2011_10706_x
crossref_primary_10_1016_j_clgc_2014_07_010
crossref_primary_10_1016_j_juro_2014_08_106
crossref_primary_10_1016_j_urolonc_2014_02_003
crossref_primary_10_1038_s41598_018_24526_5
crossref_primary_10_1158_0008_5472_CAN_10_3072
crossref_primary_10_1371_journal_pone_0026131
crossref_primary_10_1016_j_urolonc_2013_08_005
crossref_primary_10_1016_j_humpath_2024_04_012
crossref_primary_10_1186_s42047_018_0023_6
crossref_primary_10_1111_cas_14334
crossref_primary_10_1016_j_humpath_2012_11_026
crossref_primary_10_1155_2017_6794150
crossref_primary_10_1016_j_humpath_2013_07_008
crossref_primary_10_1016_j_urolonc_2016_05_031
crossref_primary_10_1016_j_critrevonc_2013_08_008
Cites_doi 10.1016/j.eururo.2004.04.008
10.1002/cncr.22195
10.1111/j.1464-410X.2004.04574.x
10.1159/000094819
10.1007/s00428-007-0370-2
10.1042/BST0370217
10.1038/ng.371
10.1007/s12032-009-9201-4
10.1111/j.1464-410X.2007.06927.x
10.1016/S0092-8674(02)00808-5
10.1038/nrc1697
10.1097/MOU.0b013e3282f1c5c1
10.1038/nrc1974
10.1038/nrc2501
10.4161/cc.1.6.263
10.1038/sj.bjc.6601741
10.1101/gad.1212704
10.1200/JCO.2001.19.3.666
10.1158/0008-5472.CAN-09-1689
10.1128/MCB.26.10.3955-3965.2006
10.1080/03008880802291915
10.1038/onc.2009.14
10.1002/mc.20420
10.1002/cncr.22677
10.1111/j.1478-3231.2008.01798.x
10.1159/000170878
10.1158/1078-0432.CCR-09-0898
10.1159/000085933
10.4161/cc.8.9.8215
10.1136/jcp.2007.050666
10.1038/ng.370
10.1101/gad.1772909
10.1016/j.juro.2006.09.038
10.1016/j.juro.2009.08.115
10.1158/0008-5472.CAN-05-1986
10.1038/modpathol.2009.1
10.1038/sj.onc.1208002
10.1507/endocrj.50.77
10.1016/j.bbapap.2007.09.008
10.1016/S0014-5793(99)00185-4
10.1158/1078-0432.CCR-04-0941
10.1038/modpathol.3800525
ContentType Journal Article
Copyright Copyright © 2010 American Cancer Society
2015 INIST-CNRS
Copyright © 2010 American Cancer Society.
Copyright_xml – notice: Copyright © 2010 American Cancer Society
– notice: 2015 INIST-CNRS
– notice: Copyright © 2010 American Cancer Society.
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7U1
7U2
C1K
7X8
DOI 10.1002/cncr.25502
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Risk Abstracts
Safety Science and Risk
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Risk Abstracts
Safety Science and Risk
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Risk Abstracts
CrossRef
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-0142
EndPage 5526
ExternalDocumentID 10_1002_cncr_25502
20939013
23438165
CNCR25502
Genre article
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: P50 CA058236
– fundername: NCI NIH HHS
  grantid: P01 CA077664
– fundername: NCI NIH HHS
  grantid: P01 CA077664-10
GroupedDBID ---
-~X
.3N
.GA
.Y3
05W
0R~
10A
1CY
1L6
1OC
24P
29B
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
6J9
6P2
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
85S
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AARRQ
AAWTL
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABHFT
ABIJN
ABIVO
ABJNI
ABLJU
ABOCM
ABPPZ
ABPVW
ABQWH
ABXGK
ACAHQ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACNCT
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEIGN
AEIMD
AENEX
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AGNAY
AHBTC
AIACR
AIAGR
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C1A
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
E3Z
EBS
EJD
EX3
F00
F01
F04
F5P
FD6
FUBAC
G-S
G.N
GNP
GODZA
GX1
H.X
HBH
HF~
HGLYW
HHY
HHZ
HZ~
IH2
IX1
J0M
JPC
KBYEO
KQQ
KZ1
L7B
LATKE
LAW
LC2
LC3
LH4
LITHE
LMP
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N4W
N9A
NF~
NNB
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
QRW
R.K
ROL
RWI
RX1
RYL
SJN
SUPJJ
TEORI
UDS
UHB
V2E
V8K
V9Y
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WJL
WOHZO
WQJ
WRC
WVDHM
WXI
WXSBR
XG1
XPP
XV2
Z0Y
ZGI
ZZTAW
~IA
~WT
.GJ
08R
3O-
AAJUZ
AAUGY
AAVGM
ABCVL
ABHUG
ABPTK
ABWRO
ACCFJ
ACXME
ADAWD
ADDAD
AEEZP
AEQDE
AFFNX
AFVGU
AGJLS
AI.
AIWBW
AJBDE
AKALU
EMOBN
H~9
IQODW
J5H
NEJ
OHT
RSU
VH1
WHG
XFK
Y6R
YQJ
ZA5
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
AAQOH
AAYXX
CITATION
7U1
7U2
C1K
7X8
ID FETCH-LOGICAL-c4932-b89a8e456fda6705daa5e16bd3aaa5deaf1e80ea92f85ac81d1e4396dbf69ec43
IEDL.DBID DR2
ISSN 0008-543X
1097-0142
IngestDate Thu Aug 15 22:41:43 EDT 2024
Fri Aug 16 07:15:02 EDT 2024
Fri Aug 23 00:55:50 EDT 2024
Sat Sep 28 07:57:50 EDT 2024
Sun Oct 22 16:08:42 EDT 2023
Sat Aug 24 01:04:09 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 23
Keywords KIP1 Gene
Prognosis
c-myc
Transitional cell carcinoma
Cancerology
phosS6
Urinary bladder
Surgery
PTEN Gene
Protooncogene
Tumor suppressor gene
Urinary system disease
Akt protein kinase
Urinary tract disease
Malignant tumor
Akt
Pten
Baldder transitional cell carcinoma
Cystectomy
Treatment
urothelial carcinoma
Urinary system
p27
C-Onc gene
Mammalian target of rapamycin
bladder
myc Gene
Bladder disease
4E-BP1
Cancer
Language English
License CC BY 4.0
Copyright © 2010 American Cancer Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4932-b89a8e456fda6705daa5e16bd3aaa5deaf1e80ea92f85ac81d1e4396dbf69ec43
Notes Fax: (443) 287‐3818
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink https://europepmc.org/articles/pmc3568488?pdf=render
PMID 20939013
PQID 1017960769
PQPubID 23462
PageCount 10
ParticipantIDs proquest_miscellaneous_812130296
proquest_miscellaneous_1017960769
crossref_primary_10_1002_cncr_25502
pubmed_primary_20939013
pascalfrancis_primary_23438165
wiley_primary_10_1002_cncr_25502_CNCR25502
PublicationCentury 2000
PublicationDate 1 December 2010
PublicationDateYYYYMMDD 2010-12-01
PublicationDate_xml – month: 12
  year: 2010
  text: 1 December 2010
  day: 01
PublicationDecade 2010
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: Hoboken, NJ
– name: United States
PublicationTitle Cancer
PublicationTitleAlternate Cancer
PublicationYear 2010
Publisher Wiley Subscription Services, Inc., A Wiley Company
Wiley-Blackwell
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
– name: Wiley-Blackwell
References 2009; 23
2009; 22
2009; 69
2009; 41
2002; 110
2006; 77
2008; 18
2007; 100
2004; 23
2008; 38
2004; 46
2002; 1
2006; 6
2006; 19
2008; 8
2010; 183
2004; 90
2003; 50
2007; 109
1999; 446
1996; 56
2009; 29
2009; 28
2004; 10
2009; 56
2010; 27
2006; 86
2008; 1784
2004; 93
2004; 18
2006; 66
2005; 103
2008; 29
2007; 177
1999; 59
2007; 450
2006; 26
2001; 19
2005; 5
2008; 47
2008; 218
2005; 75
2009; 8
2008; 61
2006; 107
2009; 37
2009; 15
2005; 14
12733712 - Endocr J. 2003 Feb;50(1):77-83
10100614 - FEBS Lett. 1999 Mar 5;446(1):55-9
19453019 - Hepatogastroenterology. 2009 Jan-Feb;56(89):6-10
16341149 - Mod Pathol. 2006 Feb;19(2):238-45
12150925 - Cell. 2002 Jul 26;110(2):163-75
19913255 - J Urol. 2010 Jan;183(1):68-75
17555476 - BJU Int. 2007 Aug;100(2):259-63
16110317 - Nat Rev Cancer. 2005 Sep;5(9):713-25
17033215 - Urol Int. 2006;77(3):255-63
17964232 - Biochim Biophys Acta. 2008 Jan;1784(1):150-8
19843858 - Cancer Res. 2009 Nov 1;69(21):8256-64
18090481 - Curr Opin Urol. 2008 Jan;18(1):1-8
18815930 - Scand J Urol Nephrol Suppl. 2008 Sep;(218):154-65
17222615 - J Urol. 2007 Feb;177(2):481-7; discussion 487
17265080 - Virchows Arch. 2007 Mar;450(3):321-8
18288642 - Mol Carcinog. 2008 Sep;47(9):678-85
19396167 - Nat Genet. 2009 May;41(5):524-6
18715846 - Ann Clin Lab Sci. 2008 Summer;38(3):195-209
15083183 - Br J Cancer. 2004 Apr 19;90(8):1543-50
15623621 - Clin Cancer Res. 2004 Dec 15;10(24):8421-5
18492014 - Liver Int. 2009 Mar;29(3):399-405
15542899 - Methods Mol Med. 2005;103:89-101
17440983 - Cancer. 2007 Jun 1;109(11):2257-67
19143635 - Biochem Soc Trans. 2009 Feb;37(Pt 1):217-22
19234517 - Oncogene. 2009 Apr 2;28(13):1594-604
11157016 - J Clin Oncol. 2001 Feb 1;19(3):666-75
19342893 - Cell Cycle. 2009 May 1;8(9):1344-51
19396168 - Nat Genet. 2009 May;41(5):619-24
Cancer. 2011 Nov 1;117(21):5021
12548012 - Cell Cycle. 2002 Nov-Dec;1(6):394-400
18846101 - Nat Rev Cancer. 2008 Nov;8(11):851-64
18984977 - Tumour Biol. 2008;29(5):311-22
16488991 - Cancer Res. 2006 Feb 15;66(4):1929-39
15286700 - Oncogene. 2004 Sep 23;23(44):7378-90
19261747 - Genes Dev. 2009 Mar 15;23(6):675-80
16648488 - Mol Cell Biol. 2006 May;26(10):3955-65
14678387 - BJU Int. 2004 Jan;93(1):143-50
19789314 - Clin Cancer Res. 2009 Oct 1;15(19):6008-17
16142350 - Oncol Rep. 2005 Oct;14(4):909-13
10397272 - Cancer Res. 1999 Jul 1;59(13):3245-50
17064593 - Zhonghua Yi Xue Za Zhi. 2006 Jul 25;86(28):1970-4
19494855 - Mod Pathol. 2009 Jun;22 Suppl 2:S70-95
15245814 - Eur Urol. 2004 Aug;46(2):200-8
8752154 - Cancer Res. 1996 Sep 1;56(17):3895-7
16123561 - Urol Int. 2005;75(2):102-6
16915295 - Nat Rev Cancer. 2006 Sep;6(9):729-34
16983702 - Cancer. 2006 Oct 15;107(8):1801-11
19301157 - Med Oncol. 2010 Jun;27(2):255-61
15314020 - Genes Dev. 2004 Aug 15;18(16):1926-45
17908805 - J Clin Pathol. 2008 May;61(5):658-64
e_1_2_7_5_2
Sgambato A (e_1_2_7_48_2) 1999; 59
e_1_2_7_3_2
e_1_2_7_9_2
e_1_2_7_7_2
e_1_2_7_19_2
e_1_2_7_17_2
e_1_2_7_15_2
e_1_2_7_13_2
e_1_2_7_41_2
e_1_2_7_11_2
e_1_2_7_43_2
e_1_2_7_45_2
e_1_2_7_47_2
e_1_2_7_26_2
e_1_2_7_49_2
e_1_2_7_28_2
Okada T (e_1_2_7_18_2) 2009; 56
Fedor HL (e_1_2_7_10_2) 2005; 103
e_1_2_7_50_2
e_1_2_7_25_2
e_1_2_7_23_2
e_1_2_7_31_2
Palit V (e_1_2_7_44_2) 2005; 14
e_1_2_7_21_2
e_1_2_7_33_2
e_1_2_7_35_2
e_1_2_7_37_2
e_1_2_7_39_2
Feng W (e_1_2_7_14_2) 2008; 38
e_1_2_7_4_2
e_1_2_7_2_2
e_1_2_7_8_2
e_1_2_7_6_2
e_1_2_7_16_2
e_1_2_7_40_2
e_1_2_7_46_2
e_1_2_7_27_2
e_1_2_7_29_2
e_1_2_7_24_2
e_1_2_7_30_2
e_1_2_7_22_2
e_1_2_7_32_2
e_1_2_7_20_2
e_1_2_7_34_2
Zhou JT (e_1_2_7_42_2) 2006; 86
e_1_2_7_36_2
e_1_2_7_38_2
Seufferlein T (e_1_2_7_12_2) 1996; 56
References_xml – volume: 8
  start-page: 1344
  year: 2009
  end-page: 1351
  article-title: Growth controls connect: interactions between c‐myc and the tuberous sclerosis complex‐mTOR pathway
  publication-title: Cell Cycle.
– volume: 15
  start-page: 6008
  year: 2009
  end-page: 6017
  article-title: Spectrum of phosphatidylinositol 3‐kinase pathway gene alterations in bladder cancer
  publication-title: Clin Cancer Res.
– volume: 59
  start-page: 3245
  year: 1999
  end-page: 3250
  article-title: Loss of P27Kip1 expression correlates with tumor grade and with reduced disease‐free survival in primary superficial bladder cancers
  publication-title: Cancer Res.
– volume: 86
  start-page: 1970
  year: 2006
  end-page: 1974
  article-title: Expression of hypoxia inducible factor‐1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof
  publication-title: Zhonghua Yi Xue Za Zhi.
– volume: 29
  start-page: 311
  year: 2008
  end-page: 322
  article-title: Current status of prognostic immunohistochemical markers for urothelial bladder cancer
  publication-title: Tumour Biol.
– volume: 19
  start-page: 238
  year: 2006
  end-page: 245
  article-title: The akt pathway in human breast cancer: a tissue‐array‐based analysis
  publication-title: Mod Pathol.
– volume: 110
  start-page: 163
  year: 2002
  end-page: 175
  article-title: mTOR interacts with raptor to form a nutrient‐sensitive complex that signals to the cell growth machinery
  publication-title: Cell.
– volume: 23
  start-page: 7378
  year: 2004
  end-page: 7390
  article-title: Prolactin induces c‐myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells
  publication-title: Oncogene.
– volume: 41
  start-page: 619
  year: 2009
  end-page: 624
  article-title: Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
  publication-title: Nat Genet.
– volume: 14
  start-page: 909
  year: 2005
  end-page: 913
  article-title: Expression of HIF‐1alpha and glut‐1 in human bladder cancer
  publication-title: Oncol Rep.
– volume: 100
  start-page: 259
  year: 2007
  end-page: 263
  article-title: Prognostic significance of p27(Kip1) expression in bladder cancer
  publication-title: BJU Int.
– volume: 8
  start-page: 851
  year: 2008
  end-page: 864
  article-title: Hypoxia signalling through mTOR and the unfolded protein response in cancer
  publication-title: Nat Rev Cancer.
– volume: 1784
  start-page: 150
  year: 2008
  end-page: 158
  article-title: PI3K/PTEN signaling in tumorigenesis and angiogenesis
  publication-title: Biochim Biophys Acta.
– volume: 56
  start-page: 3895
  year: 1996
  end-page: 3897
  article-title: Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells
  publication-title: Cancer Res.
– volume: 18
  start-page: 1
  year: 2008
  end-page: 8
  article-title: Molecular markers in bladder cancer
  publication-title: Curr Opin Urol.
– volume: 56
  start-page: 6
  year: 2009
  end-page: 10
  article-title: Rapamycin inhibits growth of cholangiocarcinoma cells
  publication-title: Hepatogastroenterology.
– volume: 28
  start-page: 1594
  year: 2009
  end-page: 1604
  article-title: The role of the birt‐hogg‐dube protein in mTOR activation and renal tumorigenesis
  publication-title: Oncogene.
– volume: 6
  start-page: 729
  year: 2006
  end-page: 734
  article-title: mTOR and cancer: insights into a complex relationship
  publication-title: Nat Rev Cancer.
– volume: 218
  start-page: 154
  year: 2008
  end-page: 165
  article-title: Molecular alterations associated with bladder cancer initiation and progression
  publication-title: Scand J Urol Nephrol Suppl.
– volume: 69
  start-page: 8256
  year: 2009
  end-page: 8264
  article-title: Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models
  publication-title: Cancer Res.
– volume: 5
  start-page: 713
  year: 2005
  end-page: 725
  article-title: Urothelial tumorigenesis: a tale of divergent pathways
  publication-title: Nat Rev Cancer.
– volume: 90
  start-page: 1543
  year: 2004
  end-page: 1550
  article-title: Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node‐negative premenopausal early breast cancer patients
  publication-title: Br J Cancer.
– volume: 27
  start-page: 255
  year: 2010
  end-page: 261
  article-title: The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma
  publication-title: Med Oncol.
– volume: 450
  start-page: 321
  year: 2007
  end-page: 328
  article-title: Co‐expression of EGF receptor, TGFalpha and S6 kinase is significantly associated with colorectal carcinomas with distant metastases at diagnosis
  publication-title: Virchows Arch.
– volume: 22
  start-page: S70
  year: 2009
  end-page: S95
  article-title: Staging and reporting of urothelial carcinoma of the urinary bladder
  publication-title: Mod Pathol.
– volume: 46
  start-page: 200
  year: 2004
  end-page: 208
  article-title: Hypoxia‐inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer
  publication-title: Eur Urol.
– volume: 93
  start-page: 143
  year: 2004
  end-page: 150
  article-title: The phosphatidylinositol‐3 kinase pathway regulates bladder cancer cell invasion
  publication-title: BJU Int.
– volume: 1
  start-page: 394
  year: 2002
  end-page: 400
  article-title: Understanding p27(kip1) deregulation in cancer: Down‐regulation or mislocalization
  publication-title: Cell Cycle.
– volume: 61
  start-page: 658
  year: 2008
  end-page: 664
  article-title: Hypoxia‐inducible factor‐1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma
  publication-title: J Clin Pathol.
– volume: 103
  start-page: 89
  year: 2005
  end-page: 101
  article-title: Practical methods for tissue microarray construction
  publication-title: Methods Mol Med.
– volume: 66
  start-page: 1929
  year: 2006
  end-page: 1939
  article-title: Pten deficiency activates distinct downstream signaling pathways in a tissue‐specific manner
  publication-title: Cancer Res.
– volume: 26
  start-page: 3955
  year: 2006
  end-page: 3965
  article-title: Hypoxia inhibits protein synthesis through a 4E‐BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells
  publication-title: Mol Cell Biol.
– volume: 19
  start-page: 666
  year: 2001
  end-page: 675
  article-title: Radical cystectomy in the treatment of invasive bladder cancer: long‐term results in 1,054 patients
  publication-title: J Clin Oncol.
– volume: 38
  start-page: 195
  year: 2008
  end-page: 209
  article-title: Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF‐kappaB pathways in human gastric adenocarcinoma
  publication-title: Ann Clin Lab Sci.
– volume: 446
  start-page: 55
  year: 1999
  end-page: 59
  article-title: Hypoxia increases the association of 4E‐binding protein 1 with the initiation factor 4E in isolated rat hepatocytes
  publication-title: FEBS Lett.
– volume: 107
  start-page: 1801
  year: 2006
  end-page: 1811
  article-title: Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer
  publication-title: Cancer.
– volume: 18
  start-page: 1926
  year: 2004
  end-page: 1945
  article-title: Upstream and downstream of mTOR
  publication-title: Genes Dev.
– volume: 37
  start-page: 217
  year: 2009
  end-page: 222
  article-title: A complex interplay between akt, TSC2 and the 2 mTOR complexes
  publication-title: Biochem Soc Trans.
– volume: 10
  start-page: 8421
  year: 2004
  end-page: 8425
  article-title: mTOR and P70 S6 kinase expression in primary liver neoplasms
  publication-title: Clin Cancer Res.
– volume: 47
  start-page: 678
  year: 2008
  end-page: 685
  article-title: Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray
  publication-title: Mol Carcinog.
– volume: 29
  start-page: 399
  year: 2009
  end-page: 405
  article-title: Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin‐resected hepatocellular carcinoma
  publication-title: Liver Int.
– volume: 183
  start-page: 68
  year: 2010
  end-page: 75
  article-title: Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer
  publication-title: J Urol.
– volume: 41
  start-page: 524
  year: 2009
  end-page: 526
  article-title: Cooperativity of TMPRSS2‐ERG with PI3‐kinase pathway activation in prostate oncogenesis
  publication-title: Nat Genet.
– volume: 23
  start-page: 675
  year: 2009
  end-page: 680
  article-title: Inactivation of p53 and pten promotes invasive bladder cancer
  publication-title: Genes Dev.
– volume: 77
  start-page: 255
  year: 2006
  end-page: 263
  article-title: Hypoxia‐inducible factors HIF‐1alpha and HIF‐2alpha expression in bladder cancer and their associations with other angiogenesis‐related proteins
  publication-title: Urol Int.
– volume: 177
  start-page: 481
  year: 2007
  end-page: 487
  article-title: Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
  publication-title: J Urol.
– volume: 50
  start-page: 77
  year: 2003
  end-page: 83
  article-title: Increased expression of phosphorylated p70S6 kinase and akt in papillary thyroid cancer tissues
  publication-title: Endocr J.
– volume: 109
  start-page: 2257
  year: 2007
  end-page: 2267
  article-title: Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy
  publication-title: Cancer.
– volume: 75
  start-page: 102
  year: 2005
  end-page: 106
  article-title: Differential PTEN protein expression profiles in superficial versus invasive bladder cancers
  publication-title: Urol Int.
– ident: e_1_2_7_45_2
  doi: 10.1016/j.eururo.2004.04.008
– volume: 59
  start-page: 3245
  year: 1999
  ident: e_1_2_7_48_2
  article-title: Loss of P27Kip1 expression correlates with tumor grade and with reduced disease‐free survival in primary superficial bladder cancers
  publication-title: Cancer Res.
  contributor:
    fullname: Sgambato A
– ident: e_1_2_7_16_2
  doi: 10.1002/cncr.22195
– ident: e_1_2_7_26_2
  doi: 10.1111/j.1464-410X.2004.04574.x
– volume: 56
  start-page: 6
  year: 2009
  ident: e_1_2_7_18_2
  article-title: Rapamycin inhibits growth of cholangiocarcinoma cells
  publication-title: Hepatogastroenterology.
  contributor:
    fullname: Okada T
– ident: e_1_2_7_43_2
  doi: 10.1159/000094819
– ident: e_1_2_7_13_2
  doi: 10.1007/s00428-007-0370-2
– ident: e_1_2_7_4_2
  doi: 10.1042/BST0370217
– ident: e_1_2_7_28_2
  doi: 10.1038/ng.371
– ident: e_1_2_7_19_2
  doi: 10.1007/s12032-009-9201-4
– volume: 38
  start-page: 195
  year: 2008
  ident: e_1_2_7_14_2
  article-title: Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF‐kappaB pathways in human gastric adenocarcinoma
  publication-title: Ann Clin Lab Sci.
  contributor:
    fullname: Feng W
– ident: e_1_2_7_47_2
  doi: 10.1111/j.1464-410X.2007.06927.x
– ident: e_1_2_7_36_2
  doi: 10.1016/S0092-8674(02)00808-5
– ident: e_1_2_7_24_2
  doi: 10.1038/nrc1697
– ident: e_1_2_7_23_2
  doi: 10.1097/MOU.0b013e3282f1c5c1
– ident: e_1_2_7_8_2
  doi: 10.1038/nrc1974
– ident: e_1_2_7_37_2
  doi: 10.1038/nrc2501
– ident: e_1_2_7_6_2
  doi: 10.4161/cc.1.6.263
– volume: 56
  start-page: 3895
  year: 1996
  ident: e_1_2_7_12_2
  article-title: Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells
  publication-title: Cancer Res.
  contributor:
    fullname: Seufferlein T
– ident: e_1_2_7_21_2
  doi: 10.1038/sj.bjc.6601741
– ident: e_1_2_7_40_2
  doi: 10.1101/gad.1212704
– ident: e_1_2_7_2_2
  doi: 10.1200/JCO.2001.19.3.666
– ident: e_1_2_7_31_2
  doi: 10.1158/0008-5472.CAN-09-1689
– ident: e_1_2_7_38_2
  doi: 10.1128/MCB.26.10.3955-3965.2006
– ident: e_1_2_7_3_2
  doi: 10.1080/03008880802291915
– ident: e_1_2_7_15_2
  doi: 10.1038/onc.2009.14
– ident: e_1_2_7_27_2
  doi: 10.1002/mc.20420
– ident: e_1_2_7_30_2
  doi: 10.1002/cncr.22677
– ident: e_1_2_7_20_2
  doi: 10.1111/j.1478-3231.2008.01798.x
– ident: e_1_2_7_50_2
  doi: 10.1159/000170878
– ident: e_1_2_7_25_2
  doi: 10.1158/1078-0432.CCR-09-0898
– volume: 103
  start-page: 89
  year: 2005
  ident: e_1_2_7_10_2
  article-title: Practical methods for tissue microarray construction
  publication-title: Methods Mol Med.
  contributor:
    fullname: Fedor HL
– volume: 86
  start-page: 1970
  year: 2006
  ident: e_1_2_7_42_2
  article-title: Expression of hypoxia inducible factor‐1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof
  publication-title: Zhonghua Yi Xue Za Zhi.
  contributor:
    fullname: Zhou JT
– ident: e_1_2_7_34_2
  doi: 10.1159/000085933
– ident: e_1_2_7_46_2
  doi: 10.4161/cc.8.9.8215
– ident: e_1_2_7_41_2
  doi: 10.1136/jcp.2007.050666
– ident: e_1_2_7_29_2
  doi: 10.1038/ng.370
– ident: e_1_2_7_33_2
  doi: 10.1101/gad.1772909
– ident: e_1_2_7_49_2
  doi: 10.1016/j.juro.2006.09.038
– ident: e_1_2_7_22_2
  doi: 10.1016/j.juro.2009.08.115
– ident: e_1_2_7_32_2
  doi: 10.1158/0008-5472.CAN-05-1986
– ident: e_1_2_7_9_2
  doi: 10.1038/modpathol.2009.1
– ident: e_1_2_7_7_2
  doi: 10.1038/sj.onc.1208002
– ident: e_1_2_7_11_2
  doi: 10.1507/endocrj.50.77
– ident: e_1_2_7_5_2
  doi: 10.1016/j.bbapap.2007.09.008
– ident: e_1_2_7_39_2
  doi: 10.1016/S0014-5793(99)00185-4
– ident: e_1_2_7_17_2
  doi: 10.1158/1078-0432.CCR-04-0941
– ident: e_1_2_7_35_2
  doi: 10.1038/modpathol.3800525
– volume: 14
  start-page: 909
  year: 2005
  ident: e_1_2_7_44_2
  article-title: Expression of HIF‐1alpha and glut‐1 in human bladder cancer
  publication-title: Oncol Rep.
  contributor:
    fullname: Palit V
SSID ssj0007253
Score 2.318718
Snippet BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is...
Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial....
Abstract BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of...
BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is...
BACKGROUNDBladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is...
SourceID proquest
crossref
pubmed
pascalfrancis
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 5517
SubjectTerms 4E‐BP1
Aged
Akt
Biological and medical sciences
Biomarkers, Tumor - metabolism
bladder
Cancer
Cystectomy
c‐myc
Female
Histology
Humans
lymph nodes
Male
mammalian target of rapamycin
Medical sciences
Middle Aged
migration
Morbidity
Mortality
Nephrology. Urinary tract diseases
p27
phosS6
Prognosis
Pten
Signal Transduction
survival
Tissue Array Analysis
TOR Serine-Threonine Kinases - metabolism
Tumors
Tumors of the urinary system
urinary bladder
Urinary Bladder Neoplasms - metabolism
Urinary Bladder Neoplasms - surgery
Urinary tract. Prostate gland
urothelial carcinoma
Urothelium
Title Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.25502
https://www.ncbi.nlm.nih.gov/pubmed/20939013
https://search.proquest.com/docview/1017960769
https://search.proquest.com/docview/812130296
Volume 116
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB5CDqFQ-n64TYNKeyp445Ut2YZcwpIQCskhNLCXYkavS2M7rNe025_SX1uN7N1lS1tob0LoYUkzo8_S6BuA95k0uRFTFxcGKYSZ0TGWOcbCcuf8fiG5pR_Fyyt5cZN9nIv5Hpys38IM_BCbAzfSjGCvScFRdcdb0lDd6MXEA-LAJElMeoSIrrfcUTkfKSiTIhZZOt9wk_LjbdWd3ej-HXZ-YtwQ0eJ3kHMXwYYt6PwhfF5__OB58mXSL9VEf_-F1_F_R_cIHozYlJ0OwvQY9mzzBA4ux9v3p_Dj7NvoNtsweojUdwwbw8jFq2mJ75mRNwj5HpEosdaxGus6HKSwweOc8ijker3yLTKKhvwVV6y2FJWkYz6rX9CLMF_jlmmKctS0NVIluhPwg2HqlizlgoXQ5kwTDbVetvXqGdycn32aXcRjbIdYZx4yxqoosbAevTmDMk-EQRR2KpVJ0aeMRTe1RWKx5K4QqD2qnlqPnaRRTpZWZ-lz2G_axr4EJnNrM5MpctbNfGsKLedJYYVTXHnzFMG79RpXdwOFRzWQNfOKprkK0xzB0c7yb4rylFjQpIjg7VoeKq-CdK-CjW37rgpWTSa--wjYH8oURJ2X8FJG8GKQpW0HSUkHT2kEH4JE_OUjq9nV7DqkXv1L4ddwj2-8cA5hf7no7RuPpZbqKOjMT0FJH_M
link.rule.ids 315,786,790,1382,27955,27956,46327,46751
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwGP2EhgRIiDssXIYRPCGlS53YSR5R2VRg7cO0SX2LfH1hcaam0Sg_hV-LPydrVQRI8BZFdi7O99kn9vE5AO8yrnPNxjYutEALM61iUeYiZoZa68cLTg3-KM7mfHqefV6wxcDNwb0wvT7EZsINMyP015jgOCF9uFUNVU4tRx4Ro5TkTZ_vDPPy4-lWPSqngwhlUsQsSxcbdVJ6uK27Mx7dvRStbxrbe1r8DnTuYtgwCB3f751W26BdiNyTr6NuJUfq-y_Kjv_9fg_g3gBPyYc-nh7CDeMewa3ZsAD_GH4cfRuYs47gXqSuJcJpgiwv16DkM0FCCNKPMJpIY0kt6jrMpZCedI7n0HW9XvsrEjREvhJrUhs0JmmJP9UtcVOYr3FBFBoduaYWWAmXBfzbEHmBneWSBHdzolCJWq2aev0Ezo-PzibTeLB3iFXmUWMsi1IUxgM4qwXPE6aFYGbMpU6FP9JG2LEpEiNKagsmlAfWY-PhE9fS8tKoLH0Ke65xZh8Iz43JdCaRr5v5q0lhKE0Kw6yk0vdQEby9_sjVZa_iUfV6zbTCZq5CM0dwsPP9N0VpikJonEXw5jogKp-FuLQinGm6tgodG0_87SMgfyhToHpeQksewbM-mLY3SEqce0ojeB9C4i8PWU3mk9Nw9PxfCr-G29Oz2Ul18mn-5QXcoRtSzkvYWy0788pDq5U8CAn0EyIgJBM
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bixMxFD4sKyyCeHcdL2tEn4TpTjOTzAz4It0t62WLLC70RYZcX9zJlLaD1p_irzUnM22pqKBvIeSec5Ivycl3AF5mXOeaDW1caIEuzLSKRZmLmBlqrd8vODV4UDyf8LPL7N2UTffg9fovTMcPsblwQ80I6zUq-Ezb4y1pqHJqPvCAGJkkr2U8pXj0OrnYkkfltOegTIqYZel0Q05Kj7d5d7ajGzOx8CNjO5cWv8OcuxA27EHjW_B53frO9OTLoF3Kgfr-C7Hj_3bvNtzswSl500nTHdgz7i4cnPfP7_fgx-m33m7WEfyJ1C6IcJqgjZdrkPCZoDkIGh-hLJHGklrUdbhJIZ3JOcahz_V65Usk6A75q1iR2qBbkgXxUe0cv4T5HFdEoZsj19QCM-GjgO8MkVe4VM5J8G1OFPJQq2VTr-7D5fj00-gs7p07xCrzmDGWRSkK4-Gb1YLnCdNCMDPkUqfCh7QRdmiKxIiS2oIJ5WH10HjwxLW0vDQqSx_AvmuceQiE58ZkOpNorZv50qQwlCaFYVZS6denCF6s57iadRweVcfWTCsc5ioMcwRHO9O_SUpTpEHjLILna3movA7iw4pwpmkXVVjWeOKrj4D8IU2B3HkJLXkEh50sbStISrx5SiN4FSTiL42sRpPRRQg9-pfEz-Dg48m4-vB28v4xXKcbi5wnsL-ct-apx1VLeRTU5yeulyLC
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Expression+status+and+prognostic+significance+of+mammalian+target+of+rapamycin+pathway+members+in+urothelial+carcinoma+of+urinary+bladder+after+cystectomy&rft.jtitle=Cancer&rft.au=Schultz%2C+Luciana&rft.au=Albadine%2C+Roula&rft.au=Hicks%2C+Jessica&rft.au=Jadallah%2C+Sana&rft.date=2010-12-01&rft.issn=1097-0142&rft.volume=116&rft.issue=23&rft.spage=5517&rft.epage=5526&rft_id=info:doi/10.1002%2Fcncr.25502&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon